Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market Outlook (2022-2032)

The global benign prostatic hyperplasia (BPH) treatment market size was valued at US$ 27.7 Billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5% from 2022 to 2032. 

The global benign prostatic hyperplasia (BPH) treatment market is estimated to be worth US$ 47.17 Billion by the end of 2032. 

In 2021, the global benign prostatic hyperplasia treatment market revenue accounted for 24% of the global cancer treatment market. The growing preference for minimally invasive surgeries is expected to drive demand for BPH surgical treatment procedures in the coming decades.

Report Attributes	Details
Anticipated Base Year Value (2021)	US$ 27.7 Billion
Expected Market Value (2022)	US$ 29 Billion
Projected Forecast Value (2032)	US$ 47.24 Billion
Global Growth Rate (2022-2032)	5% CAGR
Expected Market Share of the U.S. Market (2032)	4.9%
Anticipated Market CAGR of Europe (2022-2032)	4.6%
Major Benign Prostatic Hyperplasia Treatment Service Providers	Abbott Laboratories Allergan Plc. Astellas Pharma Inc. Asahi Kasei Corporation Boehringer Ingelheim GmbH GlaxoSmithKline Plc. Pfizer Inc. Boston Scientific Corporation Teleflex Incorporated Endo International Plc. Urologix LLC LISA Laser Olympus Corporation Teva Pharmaceutical Industries Ltd. Merck & Co. Inc.

Revenue Analysis of Benign Prostatic Hyperplasia Treatment from 2017-2021 Vs Market Projections for 2022 to 2032

The rising prevalence of benign prostatic hyperplasia (BPH) is a major factor driving the consumption of BPH treatment drugs and devices, and this trend has been accelerating in recent years. From 2017 to 2021, the global BPH prostate treatment market grew at a CAGR of 3.8%.

Some of the important factors that influence BPH treatment market growth include increased focus on healthcare, an aging population, deteriorating lifestyle, poor eating habits, hereditary inheritance of the illness, increased research and innovation, and greater availability of therapeutic approaches.

Over the projected timeframe, these factors are anticipated to favor demand for BPH homeopathy remedies, BPH relief medicine, and benign prostatic hyperplasia natural remedies.

Which are Some Prominent Drivers of the Benign Prostatic Hyperplasia Treatment Market?

The rising prevalence of benign prostatic hyperplasia is driving the market growth

BPH is a nonmalignant expansion of prostate tissue that is a prevalent trigger of lower urinary tract symptoms in men. BPH is regarded as a normal part of male aging and is hormonally reliant on the production of testosterone and dihydrotestosterone (DHT).

By the age of 60, approximately half of men have histopathologic BPH, and 90% have it by the age of 85. BPH symptoms are estimated to affect approximately 30 million men worldwide and 14 million men in the United States. (Image courtesy of WebMD LLC.)

As BPH is a representative illness that appears in men during the aging process, the increasing aging population, particularly the geriatric male segment, can be regarded as a significant driver of BPH incidence.

For instance, China is assumed to have the world's largest geriatric population; the population aged 65 and up is anticipated to account for 26.8% of the overall population by 2050, up from 10.1% in 2015. (Source: US Census Bureau). The WHO predicts that by 2050, China will have 100 million individuals aged 80 and up.

Will patent expirations have a long-term impact on the benign prostatic hyperplasia treatment market's sales revenue?

Loss of Patent Exclusivity Making Generic Drugs Profitable

Patent expirations have long influenced the revenues of the benign prostatic hyperplasia treatment market. According to the research, crucial BPH treatment drugs such as Avodart, Cialis, Jalyn, and Rapaflo will lose their patents in 2024. The absence of branded drugs creates lucrative opportunities for regional and local participants to increase investments in generic drugs and biosimilar items.

The low-cost impact of generic medicines restricts the market opportunities for branded drugs, which causes concern for leading players who invest heavily in R&D. Although generic drug sales aid in the expansion of the BPH treatment market, their revenue input is significantly lower when compared to branded drugs.

What are the Challenges Faced by the Benign Prostatic Hyperplasia Treatment Market?

The detrimental effects of BPH medications will constrain market growth

While both drugs and surgery can diagnose BPH, both have severe side effects. Alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug classes are frequently used to treat BPH.

Drowsiness, orthostatic hypotension, retrograde ejaculation, and rhinitis are all common complications of alpha-blockers. Dizziness and orthostatic hypotension are particularly concerning in the elderly because they can result in serious morbidities like falls and subsequent injuries.

Comparative View of Benign Prostatic Hyperplasia Treatment Markets

Benign Prostatic Hyperplasia Treatment Market :

Attributes	Benign Prostatic Hyperplasia Treatment Market
CAGR (2022-2032)	5%
Market Value (2032)	US$ 47.17 Billion
Growth Factor	The rising prevalence of benign prostatic hyperplasia (BPH) is a major factor driving the consumption of BPH treatment drugs and devices, and this trend has been accelerating in recent years.
Opportunity	Enhancing emphasis on healthcare and soaring relevant research in this country are predicted to be significant trends in the treatment industry through 2032.

Benign Positional Vertigo Treatment Market :

Attributes	Benign Positional Vertigo Treatment Market
CAGR (2022-2032)	4.4%
Market Value (2032)	USD 1,800 Million
Growth Factor	The rising number of cases of benign positional vertigo is spurring the benign positional vertigo treatment market forward. The benign positional vertigo treatment market is growing due to the short turnaround time and lower cost of the procedure compared to traditional methods.
Opportunity	The expanding number of patients seeking benign positional vertigo treatment, as well as its growing demand, presents a lucrative potential growth for market participants.

Which Regional Market is the Most Profitable for Benign Prostatic Hyperplasia Treatment Manufacturers?

Growing technological innovations are supplementing the development efforts of Japanese manufacturers such as Olympus Corporation, Astellas Pharma, Inc., and Asahi Kasei Corporation. The benign prostatic hyperplasia treatment market in Asia Pacific is broadening at a rapid pace, with a CAGR of 7.3% anticipated during the forecast timeframe, owing to rising demand from medical tourism and severe R&D efforts to ensure long-term supply.

North America held the largest portion of the global benign prostatic hyperplasia therapeutics market share in 2021 and is predicted to continue to dominate throughout the projected timeframe. This is due to a rise in the incidence of BPH, an unpleasant lifestyle that leads to obesity, the existence of prominent stakeholders, and an increase in healthcare expenses in the region.

The growing incidence of benign prostatic hyperplasia in men, combined with rising risk factors, will dampen the demand for sophisticated medical devices and respond as key causes driving the expansion of the benign prostatic hyperplasia treatment market. Moreover, an increase in the requirement for minimally invasive treatment, an increment in the aging populations, and advancements associated with novel and advanced BPH treatment technologies will all contribute to the growth of the benign prostatic hyperplasia treatment market in Europe.

Country-wise Analysis

Why India is anticipated to witness huge market growth?

The financial privileges of TURP surgery in India to drive market growth

According to the Fact.MR study, the typical expense of transurethral resection of the prostate (TURP) in the United States ranges from US$ 8,000 to US$ 12,000, whereas the same surgery in India costs markedly less (between US$ 1,500 and US$ 6,000). Amidst the use of cutting-edge technology and diagnostic devices by surgeons to provide optimal clinical outcomes, the financial benefits of TURP surgery in India are substantial.

This is generating a new source of revenue for the benign prostatic hyperplasia treatment market through medical tourism, which is driven primarily by patients from Western nations such as the United States and the United Kingdom. In addition, hospitals, both private and public, do not have long waitlists, and India has relaxed visa policies, making the country more appealing for medical tourism. Thus, the market for benign prostatic hyperplasia treatment in India is anticipated to grow quickly.

Why United States will emerge as a Key Market Player?

Because of its aging population, the United States is experiencing rapid expansion

Because of the rising prevalence of benign prostatic hyperplasia, there is projected to be a high demand for BPH treatment in the United States. The country is witnessing an increment in its older population, which is more vulnerable to this circumstance and thus a highly lucrative market for BPH treatment providers.

Rising R&D activities and the accessibility of BHT surgical intervention are also expected to have an impact on market potential in the United States. Moreover, enhancing emphasis on healthcare and soaring relevant research in this country are predicted to be significant trends in the treatment industry through 2032.

Country-wise Forecast CAGRs for the Benign Prostatic Hyperplasia Treatment Industry

Country	CAGR
China	5%
U.S.	4.9%
Australia	4.4%
France	4.7%

Category-wise Insights

Which end-user segment will generate high revenue?

Hospitals will strive to be General Recognized Centers of Care

The market has been classified by end user into hospitals, ambulatory surgical centers, specialty clinics, and others, with hospitals accounting for the lion's share. The growth of the benign prostatic hyperplasia treatment market will be attributed to the high accumulation of hospitals, which were early adopters of advanced technological therapeutic approaches and were primarily preferred care facilities.

However, patients' lack of willingness to stay in hospitals for lengthy periods benefits specialized clinics. During the forecast period, specialty clinics are expected to grow at a higher CAGR of more than 6.9%.

Will the Transurethral Resection of the Prostate (TURP) segment witness high demand over the forecast period?

Soaring healthcare expenses to drive TURP segment's demand

Another economic expansion factor is the advancement of transurethral resection of the prostate (TURP) as an efficient therapeutic methodology. Other variables, such as rising healthcare expense capacities for individuals, as well as major progress in healthcare infrastructure, notably in developing countries, are predicted to accelerate this segment's growth even further.

Market Competition

Key players in the Benign Prostatic Hyperplasia Treatment market are Abbott Laborites, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser, Olympus Corporation, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Manufacturers of BPH treatment devices and drugs are investing in research and development to develop innovative treatments that will provide optimal therapeutic options for people suffering from the disease. Some of the novel developments by key manufacturers are

• In January 2021, PHAREX Health Corporation introduced Pharex Tamsulosin for BPH treatment in collaboration with the Philippine Urological Association (PUA).
• UroLift launched the Advanced Tissue Control (ATC) System in 2020.
• Asahi Kasei Pharma received Chinese approval for Flivas in 2020.
• Alembic was granted FDA approval for its Abbreviated New Drug Application (ANDA) for Silodosin Capsules 4 mg and 8 mg in 2019.

Key Segments Profiled in the Benign Prostatic Hyperplasia Treatment Industry Survey

• By Treatment :

  • Drug Class
    • Alpha Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally-invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Robotic Surgeries
    • Transurethral Microwave Thermotherapy (TUMT)
    • Prostatic Urethral Lift
    • Others
  • Laser Therapy
  • Others

• By End User :

  • Hospitals
  • Ambulatory Surgical Centres
  • Specialty Clinics
  • Others

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa